Granules India receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The company will provide the necessary response to USFDA within stipulated 15 days
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Sun Pharma gets 8 observations from USFDA for Halol facility
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Subscribe To Our Newsletter & Stay Updated